A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets

Experimental Neurology

Volumn 256, Issue , 2014, Pages 126-132

  Ramsey, Chenere P ^a,b   Tansey, Malú G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HAMPTON UNIVERSITY   (United States)

Author keywords

6 OHDA; Dopaminergic; LPS; Microglia; MPTP; Neurodegeneration; Neuroinflammation; Neurotoxin; Nigrostriatal; Paraquat; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ATORVASTATIN; BETA CATENIN; CURCUMINOID; CYP2D22 PROTEIN; CYTOCHROME P450; DYNORPHIN; FUCOIDIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; ICOSAPENTAENOIC ACID; LIPOPOLYSACCHARIDE; NAPHTHAZARIN; NEUROKININ 1 RECEPTOR; NEURON RESTRICTIVE SILENCER FACTOR; NEURONAL REPRESSOR ELEMENT 1 SILENCING TRANSCRIPTION FACTOR; NEUROTOXIN; OXIDOPAMINE; PARAQUAT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT EXTRACT; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; SUBSTANCE P; SUBSTANCE P ANTAGONIST; TENUINGENIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

ANTIINFLAMMATORY ACTIVITY; BRAIN MITOCHONDRION; CELL ACTIVATION; CELL LOSS; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; HEALTH SURVEY; MICROGLIA; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROCHEMISTRY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA PARS COMPACTA;

6-OHDA; DOPAMINERGIC; LPS; MICROGLIA; MPTP; NEURODEGENERATION; NEUROINFLAMMATION; NEUROTOXIN; NIGROSTRIATAL; PARAQUAT; PARKINSON'S DISEASE;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; INFLAMMATION; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA;

EID: 84900829745     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.05.014     Document Type: Review

References (58)

1. Bernardo A., Levi G., Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. 2000, 12:2215-2223.
2. Berry C., La Vecchia C., Nicotera P. Paraquat and Parkinson's disease. Cell Death Differ. 2010, 17:1115-1125.
3. Bove J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005, 2:484-494.
4. Choi S.Y., Son T.G., Park H.R., Jang Y.J., Oh S.B., Jin B., Lee J. Naphthazarin has a protective effect on the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced Parkinson's disease model. J. Neurosci. Res. 2012, 90:1842-1849.
5. Cohen G., Heikkila R.E. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J. Biol. Chem. 1974, 249:2447-2452.
6. Cohen S.M., Ito N. A critical review of the toxicological effects of carrageenan and processed eucheuma seaweed on the gastrointestinal tract. Crit. Rev. Toxicol. 2002, 32:413-444.
7. Cui Y.Q., Jia Y.J., Zhang T., Zhang Q.B., Wang X.M. Fucoidan protects against lipopolysaccharide-induced rat neuronal damage and inhibits the production of proinflammatory mediators in primary microglia. CNS Neurosci. Ther. 2012, 18:827-833.
8. Czeh M., Gressens P., Kaindl A.M. The yin and yang of microglia. Dev. Neurosci. 2011, 33:199-209.
9. Do H., Kang N.S., Pyo S., Billiar T.R., Sohn E.H. Differential regulation by fucoidan of IFN-gamma-induced NO production in glial cells and macrophages. J. Cell. Biochem. 2010, 111:1337-1345.
10. Elin R.J., Wolff S.M. Biology of endotoxin. Annu. Rev. Med. 1976, 27:127-141.
11. Erbe D.V., Gartrell K., Zhang Y.L., Suri V., Kirincich S.J., Will S., Perreault M., Wang S., Tobin J.F. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul. Pharmacol. 2006, 45:154-162.
12. Fallon J.H., Leslie F.M., Cone R.I. Dynorphin-containing pathways in the substantia nigra and ventral tegmentum: a double labeling study using combined immunofluorescence and retrograde tracing. Neuropeptides 1985, 5:457-460.
13. Garrido-Gil P., Joglar B., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Involvement of PPAR-gamma in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J. Neuroinflammation 2012, 9:38.
14. Graeber M.B., Li W., Rodriguez M.L. Role of microglia in CNS inflammation. FEBS Lett. 2011, 585:3798-3805.
15. Hernandez-Romero M.C., Delgado-Cortes M.J., Sarmiento M., de Pablos R.M., Espinosa-Oliva A.M., Arguelles S., Bandez M.J., Villaran R.F., Maurino R., Santiago M., Venero J.L., Herrera A.J., Cano J., Machado A. Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system. Neurotoxicology 2012, 33:347-360.
16. Innamorato N.G., Lastres-Becker I., Cuadrado A. Role of microglial redox balance in modulation of neuroinflammation. Curr. Opin. Neurol. 2009, 22:308-314.
17. Iravani M.M., Sadeghian M., Leung C.C., Jenner P., Rose S. Lipopolysaccharide-induced nigral inflammation leads to increased IL-1beta tissue content and expression of astrocytic glial cell line-derived neurotrophic factor. Neurosci. Lett. 2012, 510:138-142.
18. Jankovic J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79:368-376.
19. Joglar B., Rodriguez-Pallares J., Rodriguez-Perez A.I., Rey P., Guerra M.J., Labandeira-Garcia J.L. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 2009, 109:656-669.
20. Kumar A., Sharma N., Gupta A., Kalonia H., Mishra J. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms. Brain Res. 2012, 1471:13-22.
21. Lenkei Z., Palkovits M., Corvol P., Llorens-Cortes C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front. Neuroendocrinol. 1997, 18:383-439.
22. L'Episcopo F., Serapide M.F., Tirolo C., Testa N., Caniglia S., Morale M.C., Pluchino S., Marchetti B. A Wnt1 regulated Frizzled-1/beta-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: therapeutical relevance for neuron survival and neuroprotection. Mol. Neurodegener. 2011, 6:49.
23. L'Episcopo F., Tirolo C., Testa N., Caniglia S., Morale M.C., Deleidi M., Serapide M.F., Pluchino S., Marchetti B. Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/beta-catenin signaling pathways: functional consequences for neuroprotection and repair. J. Neurosci. 2012, 32:2062-2085.
24. Liu B., Qin L., Yang S.N., Wilson B.C., Liu Y., Hong J.S. Femtomolar concentrations of dynorphins protect rat mesencephalic dopaminergic neurons against inflammatory damage. J. Pharmacol. Exp. Ther. 2001, 298:1133-1141.
25. Luchtman D.W., Meng Q., Song C. Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behav. Brain Res. 2012, 226:386-396.
26. MacDonald B.T., Tamai K., He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 2009, 17:9-26.
27. Maia S., Arlicot N., Vierron E., Bodard S., Vergote J., Guilloteau D., Chalon S. Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease. Synapse 2012, 66:573-583.
28. Moreno S., Farioli-Vecchioli S., Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123:131-145.
29. Ojha R.P., Rastogi M., Devi B.P., Agrawal A., Dubey G.P. Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J. Neuroimmune Pharmacol. 2012, 7:609-618.
30. Przedborski S., Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid. Redox Signal. 2005, 7:685-693.
31. Przedborski S., Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov. Disord. 1998, 13(Suppl. 1):35-38.
32. Reed C.E., Milton D.K. Endotoxin-stimulated innate immunity: a contributing factor for asthma. J. Allergy Clin. Immunol. 2001, 108:157-166.
33. Rigby M., O'Donnell R., Rupniak N.M. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J. Comp. Neurol. 2005, 490:335-353.
34. Sadeghian M., Marinova-Mutafchieva L., Broom L., Davis J.B., Virley D., Medhurst A.D., Dexter D.T. Full and partial peroxisome proliferation-activated receptor-gamma agonists, but not delta agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression. J. Neuroimmunol. 2012, 246:69-77.
35. Saijo K., Winner B., Carson C.T., Collier J.G., Boyer L., Rosenfeld M.G., Gage F.H., Glass C.K. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137:47-59.
36. Sanchetee P. Major symptoms and signs of Parkinson's disease. Parkinson's Disease and Movement Disorders 2008, 78-82. McGraw-Hill, New York. T. Mehrotra, K.B. Bhattacharyya (Eds.).
37. Schoenherr C.J., Anderson D.J. Silencing is golden: negative regulation in the control of neuronal gene transcription. Curr. Opin. Neurobiol. 1995, 5:566-571.
38. Schwarzer C. 30years of dynorphins-new insights on their functions in neuropsychiatric diseases. Pharmacol. Ther. 2009, 123:353-370.
39. Simola N., Morelli M., Carta A.R. The 6-hydroxydopamine model of Parkinson's disease. Neurotox. Res. 2007, 11:151-167.
40. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21:495-505.
41. Srivastava G., Dixit A., Yadav S., Patel D.K., Prakash O., Singh M.P. Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in maneb- and paraquat-induced parkinsonism in the mouse. Free Radic. Biol. Med. 2012, 52:1294-1306.
42. Stumm R., Culmsee C., Schafer M.K., Krieglstein J., Weihe E. Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium. J. Neurosci. 2001, 21:798-811.
43. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37:510-518.
44. Tejeda H.A., Shippenberg T.S., Henriksson R. The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. Cell. Mol. Life Sci. 2012, 69:857-896.
45. Thornton E., Vink R. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. PLoS One 2012, 7:e34138.
46. Tobacman J.K. Review of harmful gastrointestinal effects of carrageenan in animal experiments. Environ. Health Perspect. 2001, 109:983-994.
47. Tohda C., Nakayama N., Hatanaka F., Komatsu K. Comparison of anti-inflammatory activities of six curcuma rhizomes: a possible curcuminoid-independent pathway mediated by Curcuma phaeocaulis extract. Evid. Based Complement. Alternat. Med. 2006, 3:255-260.
48. Villar-Cheda B., Valenzuela R., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol. Aging 2012, 33:204-211.
49. Vinet-Oliphant H., Alvarez X., Buza E., Borda J.T., Mohan M., Aye P.P., Tuluc F., Douglas S.D., Lackner A.A. Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS. Am. J. Pathol. 2010, 177:1286-1297.
50. Wang Q., Shin E.J., Nguyen X.K., Li Q., Bach J.H., Bing G., Kim W.K., Kim H.C., Hong J.S. Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice. J. Neuroinflammation 2012, 9:124.
51. Westlund K.N., Denney R.M., Kochersperger L.M., Rose R.M., Abell C.W. Distinct monoamine oxidase A and B populations in primate brain. Science 1985, 230:181-183.
52. Westlund K.N., Denney R.M., Rose R.M., Abell C.W. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 1988, 25:439-456.
53. Wright J.W., Harding J.W. Brain renin-angiotensin-a new look at an old system. Prog. Neurobiol. 2011, 95:49-67.
54. Yang S., Zhang D., Yang Z., Hu X., Qian S., Liu J., Wilson B., Block M., Hong J.S. Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture. Neurochem. Res. 2008, 33:2044-2053.
55. You Z.B., Herrera-Marschitz M., Terenius L. Modulation of neurotransmitter release in the basal ganglia of the rat brain by dynorphin peptides. J. Pharmacol. Exp. Ther. 1999, 290:1307-1315.
56. Yu M., Suo H., Liu M., Cai L., Liu J., Huang Y., Xu J., Wang Y., Zhu C., Fei J., Huang F. NRSF/REST neuronal deficient mice are more vulnerable to the neurotoxin MPTP. Neurobiol. Aging 2012, 34:916-927.
57. Yuan H.L., Li B., Xu J., Wang Y., He Y., Zheng Y., Wang X.M. Tenuigenin protects dopaminergic neurons from inflammation-mediated damage induced by the lipopolysaccharide. CNS Neurosci. Ther. 2012, 18:584-590.
58. Zhou Y., Zhang Y., Li J., Lv F., Zhao Y., Duan D., Xu Q. A comprehensive study on long-term injury to nigral dopaminergic neurons following intracerebroventricular injection of lipopolysaccharide in rats. J. Neurochem. 2012, 123:771-780.